Cargando…
A prospective study of neurofibromatosis type 1 cancer incidence in the UK
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis. Individuals with NF1 are acknowle...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360616/ https://www.ncbi.nlm.nih.gov/pubmed/16786042 http://dx.doi.org/10.1038/sj.bjc.6603227 |
_version_ | 1782153093641666560 |
---|---|
author | Walker, L Thompson, D Easton, D Ponder, B Ponder, M Frayling, I Baralle, D |
author_facet | Walker, L Thompson, D Easton, D Ponder, B Ponder, M Frayling, I Baralle, D |
author_sort | Walker, L |
collection | PubMed |
description | Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis. Individuals with NF1 are acknowledged to be at increased risk of malignancy. Several studies have previously attempted to quantify this risk, but have involved relatively small study populations. We present prospective data from 448 individuals with NF1 with a total of 5705 years of patient follow-up. These data have been collected via the UK NF1 association for patients. Demographic information on the affected individuals was cross-referenced with UK cancer registry data by the UK Office of National Statistics. The overall risk of cancer was 2.7 times higher in this cohort of NF1 patients than in the general population (95% confidence interval (CI) 1.9–3.7). The cumulative risk of a malignancy by age 50 years was 20% (95% CI 14–29%); beyond this age, the risk of cancer was not significantly elevated (P=0.27). The most frequent types of cancer were connective tissue (14% risk by age 70, 95% CI 7.8–24%) and brain tumours (7.9, 95% CI 3.9–16%). There was no statistically significant excess of cancers at other sites (P=0.22). |
format | Text |
id | pubmed-2360616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23606162009-09-10 A prospective study of neurofibromatosis type 1 cancer incidence in the UK Walker, L Thompson, D Easton, D Ponder, B Ponder, M Frayling, I Baralle, D Br J Cancer Genetics and Genomics Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis. Individuals with NF1 are acknowledged to be at increased risk of malignancy. Several studies have previously attempted to quantify this risk, but have involved relatively small study populations. We present prospective data from 448 individuals with NF1 with a total of 5705 years of patient follow-up. These data have been collected via the UK NF1 association for patients. Demographic information on the affected individuals was cross-referenced with UK cancer registry data by the UK Office of National Statistics. The overall risk of cancer was 2.7 times higher in this cohort of NF1 patients than in the general population (95% confidence interval (CI) 1.9–3.7). The cumulative risk of a malignancy by age 50 years was 20% (95% CI 14–29%); beyond this age, the risk of cancer was not significantly elevated (P=0.27). The most frequent types of cancer were connective tissue (14% risk by age 70, 95% CI 7.8–24%) and brain tumours (7.9, 95% CI 3.9–16%). There was no statistically significant excess of cancers at other sites (P=0.22). Nature Publishing Group 2006-07-17 2006-06-20 /pmc/articles/PMC2360616/ /pubmed/16786042 http://dx.doi.org/10.1038/sj.bjc.6603227 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Genetics and Genomics Walker, L Thompson, D Easton, D Ponder, B Ponder, M Frayling, I Baralle, D A prospective study of neurofibromatosis type 1 cancer incidence in the UK |
title | A prospective study of neurofibromatosis type 1 cancer incidence in the UK |
title_full | A prospective study of neurofibromatosis type 1 cancer incidence in the UK |
title_fullStr | A prospective study of neurofibromatosis type 1 cancer incidence in the UK |
title_full_unstemmed | A prospective study of neurofibromatosis type 1 cancer incidence in the UK |
title_short | A prospective study of neurofibromatosis type 1 cancer incidence in the UK |
title_sort | prospective study of neurofibromatosis type 1 cancer incidence in the uk |
topic | Genetics and Genomics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360616/ https://www.ncbi.nlm.nih.gov/pubmed/16786042 http://dx.doi.org/10.1038/sj.bjc.6603227 |
work_keys_str_mv | AT walkerl aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT thompsond aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT eastond aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT ponderb aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT ponderm aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT fraylingi aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT baralled aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT walkerl prospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT thompsond prospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT eastond prospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT ponderb prospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT ponderm prospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT fraylingi prospectivestudyofneurofibromatosistype1cancerincidenceintheuk AT baralled prospectivestudyofneurofibromatosistype1cancerincidenceintheuk |